Yes, COVID-19 continues to produce new variants. The virus has evolved considerably since the early Omicron waves, and several newer subvariants are circulating worldwide. The World Health Organization is currently monitoring multiple lineages, including KP.3.1.1, NB.1.8.1, XFG, and BA.3.2, all flagged as variants under monitoring as of early 2026. JN.1 remains classified as a variant of interest. Here’s what you need to know about how these variants differ, what symptoms to expect, and how well current vaccines and treatments hold up.
Which Variants Are Circulating Now
The current landscape traces back to a lineage called BA.2.86, which spawned JN.1, then KP.2, then KP.3. Each generation picked up small mutations in the spike protein that helped it spread more effectively. KP.3.1.1 is among the most notable of the recent subvariants being tracked. Newer entrants like NB.1.8.1, XFG, and BA.3.2 are also on the WHO’s watch list, though none has yet been elevated to a full “variant of concern.”
BA.3.2 is one to watch. A CDC report published in early 2026 noted that this variant has been detected internationally since late 2024. Lab studies show it may be harder for current vaccine-generated antibodies to neutralize compared to other circulating strains. That said, the CDC has not yet observed broader community spread or evidence that BA.3.2 causes more severe illness. Seasonal transmission patterns or further mutations could change that picture.
Why These Variants Keep Appearing
Each new subvariant gains an edge over its predecessors through mutations that help the virus dodge immunity people have built up from prior infections and vaccinations. The key changes happen in the spike protein, the part of the virus that latches onto human cells and the target of all current vaccines.
Research published in mBio mapped out exactly how this happened across recent lineages. A mutation called L455S helped BA.2.86 evolve into JN.1 by improving immune evasion. JN.1 then picked up two additional mutations (R346T and F456L) that both improved immune escape and helped the virus replicate more efficiently, producing KP.2. KP.3 added yet another change (Q493E) that boosted replication fitness further. Together, the L455S and F456L mutations give these descendants strong resistance to both monoclonal antibodies and the neutralizing antibodies your body produces after infection or vaccination.
This is why immunity feels like a moving target. The virus accumulates just enough changes to partially sidestep your existing defenses, even if those defenses still prevent the worst outcomes.
Symptoms and How Long They Last
The symptom profile for current variants hasn’t changed meaningfully from earlier Omicron subvariants. You can expect the familiar combination of sore throat, congestion, cough, fatigue, body aches, and sometimes fever. Some people experience headaches or gastrointestinal symptoms. Loss of taste or smell, once a hallmark of earlier COVID strains, is much less common now.
After exposure, it typically takes five or more days before symptoms appear, though some people notice them sooner. You’re contagious one to two days before symptoms start and for a few days after they subside. Some people carry detectable live virus for up to a week after symptom onset, and symptom rebound (feeling better, then worse again) still occurs.
Most infections now cause milder illness than in earlier pandemic years. That’s likely not because the virus itself has become gentler. Instead, years of vaccinations and infections have given most people’s immune systems a strong enough foundation to fight off the virus without progressing to severe disease. People who are immunocompromised, elderly, or unvaccinated still face higher risk.
How Well the Current Vaccine Works
The 2024-2025 updated COVID vaccine provides moderate protection. CDC data from September 2024 through January 2025 found that among adults 18 and older, the vaccine reduced COVID-related emergency department and urgent care visits by 33% in the first four months after vaccination. For immunocompetent adults 65 and older, protection against hospitalization was higher, at roughly 45-46%. Adults over 65 with weakened immune systems saw about 40% protection against hospitalization.
Those numbers are lower than what earlier vaccines achieved against the original strain, but they still represent meaningful protection against the outcomes that matter most. Hospitalization rates during this period were relatively low overall, which made it impossible to calculate how well the vaccine prevented ICU admission or death specifically.
Looking ahead, the 2025-2026 vaccine has been adapted to target LP.8.1 and shows protection against predominant JN.1 strains. However, lab testing found it produced the weakest antibody response against BA.3.2 out of seven variants tested. Whether that translates to reduced real-world protection isn’t yet clear from observational data. Vaccine composition is updated regularly to try to keep pace with viral evolution.
Do Home Tests Still Work
Rapid antigen tests still detect current variants, but their sensitivity depends heavily on timing and symptoms. Overall, rapid tests catch about 47% of infections that a PCR test would find. That sounds low, but the comparison is somewhat misleading: when measured against viral culture (which detects only live, transmissible virus rather than lingering genetic fragments), sensitivity jumps to 80%.
The key factor is when you test. If you have symptoms, sensitivity rises to 56% compared with PCR and 85% compared with culture. If you have a fever, it climbs further to 77% and 94%, respectively. Testing on a day with no symptoms drops sensitivity dramatically, to just 18% against PCR. The peak window for a positive rapid test is about three days after symptoms begin.
The practical takeaway: if you feel sick, wait a day or two after symptoms start before testing. A negative result on day one doesn’t rule out infection. Testing again 24 to 48 hours later significantly improves accuracy. If you’re testing without symptoms (before visiting a vulnerable person, for example), a single negative rapid test offers limited reassurance.
Do Treatments Still Work
The main antiviral treatments developed for COVID remain effective against current variants because they target viral replication machinery rather than the spike protein, so the mutations driving immune evasion don’t affect how these drugs work. In clinical trials, the leading prescription antiviral (sold as Paxlovid) cleared the virus roughly 84% faster than no treatment, cutting the viral clearance half-life from about 15.5 hours to 8.5 hours. The other available antiviral (molnupiravir) was less potent, clearing virus about 37% faster than no treatment, with a half-life of 11.6 hours. Paxlovid outperformed molnupiravir by about 25% in head-to-head comparison.
These treatments work best when started within the first five days of symptoms and are primarily recommended for people at higher risk of severe illness. Availability and eligibility criteria vary, so checking with a healthcare provider or pharmacy is the most direct route if you test positive and have risk factors.